Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3529149 | 0.90 | HSD11B1 (0.41) | HSD11B1CYP3A4CNR1CNR2TP53 | |
| SCHEMBL3531568 | 0.81 | HSD11B1 (0.61) | HSD11B1CYP3A4ADRA1BADRA1DADRA1A | |
| SCHEMBL3530307 | 0.80 | HSD11B1 (0.43) | HSD11B1CYP3A4CNR1CNR2TP53 | |
| SCHEMBL3531741 | 0.80 | HSD11B1 (0.48) | HSD11B1CYP3A4ADRA1BADRA1DADRA1A | |
| SCHEMBL3534235 | 0.78 | HSD11B1 (0.39) | HSD11B1CYP3A4CNR1CNR2TP53 | |
| SCHEMBL4365844 | 0.77 | HSD11B1 (0.73) | HSD11B1CYP3A4 | |
| SCHEMBL3531974 | 0.76 | HSD11B1 (0.45) | HSD11B1CYP3A4SMN1; SMN2 | |
| SCHEMBL3530675 | 0.74 | P2RX7 (0.38) | HSD11B1CYP3A4SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL3527399 | 0.71 | HSD11B1 (0.43) | HSD11B1CYP3A4 | |
| SCHEMBL3526953 | 0.71 | HSD11B1 (0.51) | HSD11B1CYP3A4HTR2AHTR2CL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652057-B2 | Pyrazolones as 11b-HSD1 inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | claimed |
| EP-1924562-A2 | PYRAZOLONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | claimed |
| WO-2007025880-A2 | PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | claimed |
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | claimed |
| US-7652057-B2 | Pyrazolones as 11b-HSD1 inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1924562-A2 | PYRAZOLONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007025880-A2 | PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | HSD11B1, HSD17B1, HSD17B7 | HSD11B1 1/4885CYP3A4 45/4885CNR1 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.